Matches in Nanopublications for { ?s <http://www.w3.org/2000/01/rdf-schema#label> ?o ?g. }
- name label "the name of the workshop" assertion.
- workshoptype label "choose the type of the workshop" assertion.
- workshop label "short ID of workshop" assertion.
- assertion label "Defining an M4M workshop" assertion.
- somebodyElse label "ORCID identifier of the person to be attributed" assertion.
- assertion label "Attributed to somebody else" assertion.
- cohort label "Adults" assertion.
- association label "Recently, off label use of modafinil (MOD), an approved medication for treatment of sleep disturbances, has been tested as a therapeutic for cocaine and methamphetamine use disorder. Positive results have been found in subjects dependent on psychostimulants without concurrent abuse of other substances." assertion.
- MONDO_0002494 label "substance-related disorder" assertion.
- MONDO_0002494 label "substance-related disorder" assertion.
- MONDO_0002494 label "Substance-related disorder" assertion.
- cohort label "Adults" assertion.
- association label "Recently, off label use of modafinil (MOD), an approved medication for treatment of sleep disturbances, has been tested as a therapeutic for cocaine and methamphetamine use disorder. Positive results have been found in subjects dependent on psychostimulants without concurrent abuse of other substances." assertion.
- cohort label "Adults" assertion.
- association label "Recently, off label use of modafinil (MOD), an approved medication for treatment of sleep disturbances, has been tested as a therapeutic for cocaine and methamphetamine use disorder. Positive results have been found in subjects dependent on psychostimulants without concurrent abuse of other substances." assertion.
- cohort label "children and adolescents" assertion.
- association label "It is also commonly used as an off-label medication to treat children and adolescents with bipolar depression, although the FDA has not approved quetiapine for this purpose." assertion.
- association label "Trazodone is also used off-label for anxiety, Alzheimer disease, substance abuse, bulimia, and fibromyalgia due to its serotonergic receptor antagonism and serotonin reuptake inhibiting effects." assertion.
- cohort label "Adults" assertion.
- cohort label "Adults" assertion.
- association label "Trazodone is also used off-label for anxiety, Alzheimer disease, substance abuse, bulimia, and fibromyalgia due to its serotonergic receptor antagonism and serotonin reuptake inhibiting effects." assertion.
- cohort label "Adults" assertion.
- association label "It also has off label use as monotherapy or adjunctive therapy for the treatment of mania, restless leg syndrome, insomnia, tardive dyskinesia, and REM sleep behavior disorder." assertion.
- association label "It also has off label use as monotherapy or adjunctive therapy for the treatment of mania, restless leg syndrome, insomnia, tardive dyskinesia, and REM sleep behavior disorder." assertion.
- cohort label "Adults" assertion.
- association label "A retrospective chart review evaluated outcomes for 5 young adult inpatients with treatment-resistant schizophrenia who were prescribed off-label oxytocin (OT; 10 IU/sublingual, 1 time per day, to 20 IU/sublingual, 3 times per day) after their therapeutic response to clozapine plateaued (dose range: 200 to 600 mg). The augmented treatment was well tolerated and continued for at least 1 year after discharge from the hospital, with continued outpatient follow-up by the treating psychiatrist. Evaluation included the Positive and Negative Syndrome Scale and clinical review based on both self and parent/guardian reports." assertion.
- cohort label "Adults" assertion.
- association label "The drug has sedative, antiemetic, anxiolytic, and appetite stimulant effects, which explains its off-label use for the following conditions: insomnia, panic disorder, post-traumatic stress disorder, obsessive-compulsive disorder, generalized anxiety disorder, social anxiety disorder, headaches, and migraines." assertion.
- association label "The drug has sedative, antiemetic, anxiolytic, and appetite stimulant effects, which explains its off-label use for the following conditions: insomnia, panic disorder, post-traumatic stress disorder, obsessive-compulsive disorder, generalized anxiety disorder, social anxiety disorder, headaches, and migraines." assertion.
- cohort label "Adults" assertion.
- association label "The drug has sedative, antiemetic, anxiolytic, and appetite stimulant effects, which explains its off-label use for the following conditions: insomnia, panic disorder, post-traumatic stress disorder, obsessive-compulsive disorder, generalized anxiety disorder, social anxiety disorder, headaches, and migraines." assertion.
- cohort label "Adults" assertion.
- cohort label "Adults" assertion.
- association label "The drug has sedative, antiemetic, anxiolytic, and appetite stimulant effects, which explains its off-label use for the following conditions: insomnia, panic disorder, post-traumatic stress disorder, obsessive-compulsive disorder, generalized anxiety disorder, social anxiety disorder, headaches, and migraines." assertion.
- association label "We performed a chart review of suicidal adult depressed patients with comorbid chronic pain and opioid use disorder who received off-label buprenorphine in outpatient and inpatient settings in a university hospital between 2013 and 2016." assertion.
- cohort label "Adults" assertion.
- cohort label "Adults" assertion.
- association label "Sedating antidepressants (e.g., amitriptyline, trazodone, mirtazapine) are often prescribed off-label as sleeping aids" assertion.
- association label "Sedating antidepressants (e.g., amitriptyline, trazodone, mirtazapine) are often prescribed off-label as sleeping aids" assertion.
- cohort label "Adults" assertion.
- cohort label "Children and adolescents" assertion.
- association label "Melatonin (97%), trazodone (81%), and quetiapine (73%) were rated by a majority of respondents as effective. Doxepin, zaleplon, tricyclic antidepressants, zolpidem, or lorazepam were rarely prescribed due to lack of evidence and/or concerns about adverse effects, long-term safety, suitability for youth, suicidality, and dependence/tolerance." assertion.
- cohort label "Children and adolescents" assertion.
- association label "Melatonin (97%), trazodone (81%), and quetiapine (73%) were rated by a majority of respondents as effective. Doxepin, zaleplon, tricyclic antidepressants, zolpidem, or lorazepam were rarely prescribed due to lack of evidence and/or concerns about adverse effects, long-term safety, suitability for youth, suicidality, and dependence/tolerance." assertion.
- cohort label "Children and adolescents" assertion.
- association label "Melatonin (97%), trazodone (81%), and quetiapine (73%) were rated by a majority of respondents as effective. Doxepin, zaleplon, tricyclic antidepressants, zolpidem, or lorazepam were rarely prescribed due to lack of evidence and/or concerns about adverse effects, long-term safety, suitability for youth, suicidality, and dependence/tolerance." assertion.
- cohort label "Elderly; adults" assertion.
- association label "Antipsychotics, e.g. quetiapine, have been commonly used off-label to control the burdensome symptoms, though they cause serious side effects and further cognitive impairment." assertion.
- cohort label "Elderly; adults" assertion.
- association label "Prescriptions for antipsychotic medications continue to increase across many brain disorders, including off-label use in children and elderly individuals." assertion.
- somebodyElse label "ORCID identifier of the person to be attributed" assertion.
- assertion label "Attributed to somebody else" assertion.
- M4M-metadata label "M4M metadata workshop" assertion.
- M4M-metadata label "M4M metadata workshop" assertion.
- M4M-metadata label "M4M metadata workshop" assertion.
- M4M-metadata label "M4M metadata workshop" assertion.
- M4M-metadata label "M4M metadata workshop" assertion.
- M4M-variable label "M4M variable workshop" assertion.
- M4M-variable label "M4M variable workshop" assertion.
- M4M-variable label "M4M variable workshop" assertion.
- M4M-variable label "M4M variable workshop" assertion.
- M4M-variable label "M4M variable workshop" assertion.
- M4M-governance label "M4M governance workshop" assertion.
- M4M-governance label "M4M governance workshop" assertion.
- M4M-governance label "M4M governance workshop" assertion.
- M4M-governance label "M4M governance workshop" assertion.
- M4M-governance label "M4M governance workshop" assertion.
- date label "date of the workshop (e.g. 2020-12-01)" assertion.
- workshoptype label "choose the type of the workshop" assertion.
- workshop label "short ID of workshop" assertion.
- name label "the name of the workshop" assertion.
- assertion label "Defining an M4M workshop" assertion.
- name label "the name of the workshop" assertion.
- date label "date of the workshop (e.g. 2020-12-01)" assertion.
- workshop label "short ID of workshop" assertion.
- assertion label "Defining a FIP workshop" assertion.
- cohort label "Adults" assertion.
- association label "Single dispensings of haloperidol and amitriptyline may be related to off-label use for indications where evidence of risks and benefits is lacking, such as behavioural disturbances in dementia and insomnia." assertion.
- cohort label "Adults" assertion.
- association label "However, studies have demonstrated that of all the antipsychotics, quetiapine is the most frequently used off-label to treat conditions such as insomnia and post-trau- matic stress disorder (McKean and Monasterio, 2012) and has been flagged as the most concerning in terms of lack of evidence to support these indications and potential to cause harm (Walton et al., 2008)." assertion.
- MONDO_0005146 label "post-traumatic stress disorder" assertion.
- MONDO_0005146 label "post-traumatic stress disorder" assertion.
- MONDO_0005146 label "post-traumatic stress disorder" assertion.
- MONDO_0005146 label "Post-traumatic stress disorder" assertion.
- MONDO_0005146 label "Post-traumatic stress disorder" assertion.
- association label "Sodium oxybate is approved only for adults, thus its use in children is only on an off-label basis." assertion.
- cohort label "Children" assertion.
- MONDO_0021107 label "Narcolepsy" assertion.
- association label "However, other atypical antipsychotics, such as lurasidone, are often considered for off-label use in the treatment of irritability, whether because of tolerability issues with risperidone and aripiprazole or because of the drug-refractory nature of this symptom cluster." assertion.
- cohort label "Children and adolescents" assertion.
- MONDO_0005258 label "autism spectrum disorder" assertion.
- cohort label "Adults" assertion.
- association label "The most commonly reported diagnosis treated was Major Depressive Disorder (72.2%), followed by Bipolar Disorder (15.1%), and Posttraumatic Stress Disorder (5.7%). Most providers (87.7%) reported administering ketamine via an intravenous route, with a minority reporting using an oral (22.8%) or an intranasal (19.3%) formulation." assertion.
- MONDO_0004985 label "Bipolar disorder" assertion.
- MONDO_0004985 label "Bipolar disorder" assertion.
- MONDO_0004985 label "Bipolar disorder" assertion.
- MONDO_0004985 label "Bipolar disorder" assertion.
- MONDO_0004985 label "Bipolar disorder" assertion.
- MONDO_0004985 label "Bipolar disorder" assertion.
- MONDO_0004985 label "Bipolar disorder" assertion.